Insulet Co. (NASDAQ:PODD) Shares Sold by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC lessened its stake in Insulet Co. (NASDAQ:PODD) by 8.0% during the fourth quarter, Holdings Channel reports. The firm owned 1,452 shares of the medical instruments supplier’s stock after selling 127 shares during the period. Revolve Wealth Partners LLC’s holdings in Insulet were worth $379,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its holdings in Insulet by 10.0% in the second quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock valued at $29,618,000 after acquiring an additional 13,351 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Insulet in the 2nd quarter valued at about $158,000. Sei Investments Co. grew its holdings in shares of Insulet by 148.6% during the 2nd quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock worth $5,911,000 after purchasing an additional 17,507 shares during the period. Public Sector Pension Investment Board increased its position in Insulet by 73.6% during the 2nd quarter. Public Sector Pension Investment Board now owns 2,699 shares of the medical instruments supplier’s stock worth $545,000 after purchasing an additional 1,144 shares in the last quarter. Finally, MBB Public Markets I LLC purchased a new position in Insulet in the second quarter valued at approximately $955,000.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of research reports. Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Citigroup boosted their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Raymond James increased their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Canaccord Genuity Group boosted their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Trading Down 1.6 %

Shares of NASDAQ PODD opened at $275.89 on Tuesday. The stock has a market capitalization of $19.35 billion, a P/E ratio of 47.24, a PEG ratio of 3.50 and a beta of 1.22. The stock’s 50 day moving average price is $267.55 and its two-hundred day moving average price is $236.30. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $282.87.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. During the same period last year, the business posted $0.71 earnings per share. On average, analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.